Fig. 2
From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic
Kaplan–Meier estimates of the risk of MACE and all-cause mortality during the non-COVID-19 and COVID-19 pandemic periods. Comparison of 30-day major adverse cardiovascular event-free survival rate between a STEMI and b NSTEMI patients in the non-COVID-19 and COVID-19 pandemic periods. Comparison of 30-day all-cause death-free survival rate between c STEMI and d NSTEMI patients in the non-COVID-19 and COVID-19 pandemic periods